Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Kahl Weighs the Complexities of Treatment Selection in Indolent Lymphoma

April 15th 2020

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Dr. Kahl on Efficacy of Targeted Agents in Relapsed/Refractory Indolent Lymphomas

April 15th 2020

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Dr. Goodman on the Need for Molecular Subtyping in T-Cell Lymphomas

April 15th 2020

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Dr. Abdul-Hay on the Future of Targeted Therapy in ALL

April 14th 2020

Mohammad Maher Abdul-Hay, MD, discusses the future of targeted therapy in acute lymphoblastic leukemia.

Dr. Jain on GVHD From Allogeneic Stem Cell Transplant

April 14th 2020

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Dr. Schmaier on the Secondary Management of Thrombosis in Hematologic Malignancies

April 14th 2020

Alvin H. Schmaier, MD, discusses the secondary management of thrombosis in patients with hematologic malignancies.

Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia

April 14th 2020

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

OncLive Saturday Spotlight: A Morning With NYU Langone Perlmutter Cancer Center

April 11th 2020

This week we have collaborated with NYU Langone Health to highlight important topics facing oncologists today. Join us on Saturday, May 9, 2020 at 11 AM EDT.

Dr. Patel on Data From the MEDALIST Trial in Low-Risk MDS

April 11th 2020

Prapti Patel, MD, discusses data from the MEDALIST trial on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndromes.

CML Research Aims to Improve a "Magic Bullet"

April 10th 2020

The approval of imatinib almost 20 years ago heralded the arrival of the targeted therapy era in oncology and thrust the ABL1 kinase into the limelight.

Gilteritinib Takes Step Toward Chinese Approval for FLT3+ AML

April 10th 2020

The China National Medical Products Administration has accepted an application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive acute myeloid leukemia.

Homing in on Clinical Advances in Hematologic Malignancies in Chicago

April 9th 2020

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.

Fresh Options Are Emerging for Relapsed DLBCL

April 7th 2020

Although considerable progress has been made in treating diffuse large B-cell lymphoma since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory disease, which is associated with considerable morbidity and mortality.

Dr. Barr on Umbralisib/Ublituximab/Venetoclax in Relapsed/Refractory CLL

April 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Goodman on the Importance of the ECHELON-2 Data in PTCL

April 4th 2020

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

FDA Approves Luspatercept for MDS-Associated Anemia

April 4th 2020

The FDA has approved luspatercept for the treatment of anemia in patients with myelodysplastic syndromes.

MRD Assessment Gains Momentum in Hematologic Malignancies

April 3rd 2020

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

Rituximab Biosimilar Ruxience Approved in Europe

April 2nd 2020

The European Commission has approved the rituximab biosimilar Ruxience for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris

FDA Grants Remestemcel-L Priority Review for Pediatric GVHD

April 1st 2020

The FDA has granted remestemcel-L a priority review designation for the treatment of children with steroid-refractory acute graft versus host disease.

Dr. Altomare on Treatment Options in ITP

April 1st 2020

Ivy P. Altomare, MD, discusses treatment options for patients with immune thrombocytopenia purpura.